Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,295 people get ACAD articles and Market Currents by email alert.
Get email alerts on ACAD »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Business Wire (Mon, 9:00AM)
-
-
Business Wire (May 15, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
-
-
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013Business Wire (Apr 25, 2013)
-
-
-
-
-
-
-
-
-
ACADIA Pharmaceuticals, Inc. Q3 2009 Earnings Conference CallMon, Nov 9, 2009
-
Acadia Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptMon, Mar 9, 2009
-
ACADIA Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptWed, Nov 5, 2008
-
ACADIA Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptMon, May 5, 2008
-
ACADIA Pharmaceuticals Inc. Q4 2007 Earnings Call TranscriptTue, Mar 11, 2008
-
ACADIA Pharmaceuticals Inc. Q4 2007 Earnings Call TranscriptWed, Mar 5, 2008
-
Acadia Pharmaceuticals Q3 2007 Earnings Call TranscriptMon, Nov 5, 2007
-
Business Wire (Mon, 9:00AM)
-
Business Wire (May 15, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013Business Wire (Apr 25, 2013)
-
at MarketWatch.com (Apr 23, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 11, 2013)
-
at MarketWatch.com (Apr 9, 2013)
-
at CNBC.com (Apr 4, 2013)
-
at CNBC.com (Mar 22, 2013)
-
at CNBC.com (Mar 18, 2013)
-
Business Wire (Mar 13, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 5, 2013)
-
at CNBC.com (Jan 22, 2013)
ACAD vs. ETF Alternatives
Company Description
We are a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. We currently are developing a portfolio consisting of four product candidates including our most advanced compound, pimavanserin,... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 14, 4:14 PM Acadia Pharmaceuticals (ACAD) announces a public offering. Size and terms of the offering weren't disclosed. Jefferies and Cowen are acting as the joint book-running managers for the offering. Shares -5% AH. Comment! [Healthcare, On the Move]
- Tuesday, May 7, 8:05 PM ACADIA (ACAD): Q1 EPS of -$0.08 in-line. Revenue of $417K misses by $33K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, April 22, 11:17 AM Acadia Pharmaceuticals (ACAD +8.1%) spikes higher this morning, breaking out of a technical range on no specific news. The stock has been considerably volatile over the past month, having risen over 700% since November of last year on the back of strong results from its Parkinson's drug Pimavanserin. Comment! [Healthcare, On the Move]
- Sunday, April 14, 8:25 AM The reconstitution of the Russell indexes coming up in June, Credit Suisse aims to anticipate who's in and who's out. The rules-based approach of the Russell 2000 has allowed arbitragers to profit each summer by front-running the moves, making the Russell 2000 ETF (IWM) a poorer play for small cap fans than IJR . Expected among the top 25 adds are ARCP, SRPT, PBYI, ACAD, and WSTC. Among the top 25 deletes: CPST, FCEL, CHKE, OMER, and EML. Comment! [Quick Ideas]
-
Thursday, April 11, 12:49 PM
Midday top 10 gainers: ACAD +55%. RNIN +26%. RAD +18%. ZUMZ +15%. MEA +13%. BIOL +12%. MGT +12%. PBTH +12%. MPAC +11%. TVL +11%.
Midday top 10 losers: LEDS -17%. FTNT -14%. ROYL -14%. NTIC -16%. HXM -11%. CREG -11%. PRMW -10%. GNVC -10%. SGYP -10%. OCZ -10%. Comment! [On the Move] -
Thursday, April 11, 9:10 AM
Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move] - Thursday, April 11, 8:05 AM Acadia Pharmaceuticals (ACAD) soars 51% after saying that the results of a Phase III trial of its Pimavanserin drug, plus other data, are enough for the company to file an application for FDA approval. Acadia will not now conduct a confirmatory phase III trial that was due to start this month. Pimavanserin is designed to treat Parkinson's disease psychosis. (PR) 4 Comments [Healthcare, On the Move]
- Monday, March 25, 12:17 PM Acadia Pharmaceuticals (ACAD +10.1%) gets a big bump on a notable mention from Jim Cramer last Friday CNBC's on Mad Money. "This is the real deal," He says. "There was some profit taking this week, but you should hold onto it. ACAD is a fantastic spec." Additionally, Seeking Alpha contributor Brian Nichols added his two cents as well, calling the stock the safest bet in the biotech space right now after Pimavanserin's encouraging Phase 3 trial results. 1 Comment [Healthcare, On the Move]
- Thursday, March 21, 3:43 PM Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate Pimavanserin worked very well reducing hallucinations and delusions related to Parkinson's Disease during Phase III testing. 1 Comment [Healthcare, On the Move]
-
Thursday, March 21, 12:57 PM
Midday top 10 gainers: ACAD +29%. CMT +19%. EGLE +17%. ANAC +17%. DRAM +18%. HNR +14%. ECT +14%. AFFY +13%. NICK +13%. GNK +12%.
Midday top 10 losers: GMO -18%. BLDP -18%. AMBT -15%. SCHL -15%. CIMT -13%. AQ -13%. CHRM -12%. VTNR -11%. PSUN -10%. CSUN -9%. Comment! [On the Move] -
Thursday, March 21, 9:10 AM
Premarket gainers: ITMN +12%. CBLI +9%. ACAD +7%. AFFY +6%.
Losers: CIMT -12%. SCHL -11%. BLDP -9%. ORCL -8%. GES -7%. Comment! [On the Move] - Thursday, March 21, 8:31 AM Acadia (ACAD) +6.4% after saying that its Pimavanserin performed well in a Phase III trial, showing a "robust and consistent efficacy...across a wide array of study measures" and confirming previous "positive top-line results." Twice as many patients treated with pimavanserin were rated as "very much improved or much improved" vs those given a placebo. (PR) Comment! [Healthcare, On the Move]
- Tuesday, March 19, 10:17 AM Acadia Pharmaceuticals (ACAD +1.7%) gets a lift this morning after Jefferies initiates coverage with a Buy and a $13 price target. The firm says that its lead drug in development, pimavanserin, is a treament for Parkinson's disease psychosis for which there is currently no FDA-approved counterpart. ACAD recently reported positive Phase 3 data, and Jefferies sees the drug as a highly attractive licensing/acquisition target for pharma companies. Comment! [Healthcare, On the Move]
-
Tuesday, March 19, 9:10 AM
Premarket gainers: NPSP +10%. SKUL +7%. ABC +6%. ACAD +5%.
Losers: AFFY -59%. HNR -46%. MTSL -30%. STSI -11%. CAH -8%. DSW -7%. HPT -6%. Comment! [On the Move] - Tuesday, March 12, 4:29 PM ACADIA (ACAD): Q4 EPS of -$0.11 misses by $0.02. Revenue of $380K misses by $90K. Shares -0.5% AH. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Monday, January 28, 12:45 PM
Midday top 10 gainers: KERX +79%. FURX +51%. SHIP +39%. CTC +18%. HGSH +17%. SINO +14%. RSH +12%. CPBC +11%. OCZ +11%. ACAD +10%.
Midday top 10 Losers: NVGN -61%. RPRX -27%. JOSB -18%. TRMD -16%. BYFC -15%. JVA -12%. DDD -11%. PRCP -10%. SSYS -9%. AKS -8%. Comment! [On the Move]
-
- View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for May 15 2013 | $ACAD $ALXA $CETV $CSIQ $SCTY $SODA $SPU | SharePlanner http://bit.ly/13xbTQb - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
ACADIA Pharmaceuticals ($ACAD) has gained 800% over the last 52-weeks. Steps look like institutional buying. http://yhoo.it/ZjLk0B;c= - View all 0 replies
-
- View all 0 replies
-
- View all 5 replies
-
-
-
- View all 0 replies
-
Perkins Cove
$ACAD, good trade for those that could trade @7:00am in pre mkt.... http://seekingalpha.com/n/k39t - View all 2 replies
-
Perkins Cove: I saw a low of 10.75, and a high of 12.50. My broker doesn't start until 8:00am, so no position. Be careful who you pick for a broker.
-
Perkins Cove: I understand Scottrade and Fidelity start @ 7:00. Any others...?
-
StockConsultant
$ACAD continuation breakout watch above 8.57 target 10.16 for a 22.3% gain, stock charts and analysis http://goo.gl/Szq62 - View all 0 replies
LATEST REPLIES
-
- View all 5 replies
-
-
-
- View all 1 replies
-
-
Perkins Cove
$ACAD, good trade for those that could trade @7:00am in pre mkt.... http://seekingalpha.com/n/k39t - View all 2 replies
-
Perkins Cove: I saw a low of 10.75, and a high of 12.50. My broker doesn't start until 8:00am, so no position. Be careful who you pick for a broker.
-
Perkins Cove: I understand Scottrade and Fidelity start @ 7:00. Any others...?
-
Brian Nichols
After data $ACAD will have $700 million market cap by end of week. It was significantly undervalued - View all 7 replies
-
-
Brian Nichols: I actually bought @ $5.20, but it's only for a trade. I will probably sell tomorrow and then look 4 a better opportunity n the next 2 months
-
- View all 3 replies
-
-
-
Scott Matusow
I cant buy ACAD now because ATRS is my claim. No way I will sell a single share of it. I just know it will be acquired in the next year. - View all 10 replies
-
-
TDPeterson123: Was just curious - appreciate your consideration. I'm not selling any ATRS. No. Do you advise keeping a "limit" in place, & how long?
-
Scott Matusow
I am looking at Acadia Pharma (ACAD) for this week. like what I see with it. Risky pick as a developmental bio, but has large upside to it. - View all 1 replies
-
